Baxter International Inc. (BAX) Receives $52.71 Consensus PT from Analysts
Shares of Baxter International Inc. (NYSE:BAX) have been assigned a consensus recommendation of “Hold” from the fourteen research firms that are currently covering the company. One equities research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $52.71.
Several brokerages have commented on BAX. JPMorgan Chase & Co. boosted their price target on shares of Baxter International from $45.00 to $48.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 27th. RBC Capital Markets reissued a “hold” rating and set a $50.00 price target (up from $47.00) on shares of Baxter International in a research report on Wednesday, July 27th. Zacks Investment Research cut shares of Baxter International from a “hold” rating to a “sell” rating in a research report on Tuesday, July 19th. Barclays PLC began coverage on shares of Baxter International in a research report on Thursday, September 15th. They set an “overweight” rating and a $52.00 price target on the stock. Finally, Royal Bank Of Canada boosted their price objective on shares of Baxter International from $47.00 to $50.00 and gave the stock a “sector perform” rating in a research note on Wednesday, July 27th.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Arbitrage SA raised its position in shares of Baxter International by 753.5% in the second quarter. BNP Paribas Arbitrage SA now owns 2,281,030 shares of the company’s stock worth $103,148,000 after buying an additional 2,013,786 shares during the last quarter. Ameriprise Financial Inc. raised its position in shares of Baxter International by 88.0% in the third quarter. Ameriprise Financial Inc. now owns 4,032,342 shares of the company’s stock worth $191,946,000 after buying an additional 1,887,115 shares during the last quarter. Analytic Investors LLC acquired a new position in shares of Baxter International during the second quarter worth about $77,247,000. Emerald Acquisition Ltd. acquired a new position in shares of Baxter International during the second quarter worth about $45,004,000. Finally, Smith Asset Management Group LP acquired a new position in shares of Baxter International during the second quarter worth about $32,281,000. Hedge funds and other institutional investors own 84.55% of the company’s stock.
Shares of Baxter International (NYSE:BAX) opened at 46.82 on Friday. The stock has a 50 day moving average price of $47.56 and a 200-day moving average price of $46.32. The stock has a market cap of $25.47 billion, a price-to-earnings ratio of 5.24 and a beta of 0.88. Baxter International has a 12-month low of $34.06 and a 12-month high of $50.16.
Baxter International (NYSE:BAX) last issued its quarterly earnings results on Tuesday, October 25th. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.45 by $0.11. Baxter International had a net margin of 48.68% and a return on equity of 11.43%. The firm had revenue of $2.56 billion for the quarter, compared to analysts’ expectations of $2.67 billion. During the same period in the previous year, the firm posted $0.41 EPS. The company’s revenue for the quarter was up 2.9% on a year-over-year basis. Equities analysts anticipate that Baxter International will post $1.91 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, January 3rd. Shareholders of record on Friday, December 2nd will be given a dividend of $0.13 per share. The ex-dividend date is Wednesday, November 30th. This represents a $0.52 dividend on an annualized basis and a dividend yield of 1.11%. Baxter International’s payout ratio is presently 5.83%.
About Baxter International
Baxter International Inc, through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services.
Receive News & Stock Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related stocks with our FREE daily email newsletter.